Amsterdam Molecular Therapeutics Successfully Raised € 14.3 m

Amsterdam – Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today that it has successfully raised € 14.3 m in gross proceeds through a private placement of new shares with institutional investors, other qualifying investors who subscribed for at least € 50,000 per investor in various jurisdictions and the members of the Board of Management (the “Private Placement”). Pursuant to the Private Placement AMT will issue 8,435,294 new ordinary shares with a nominal value of € 0.04 each for an offer price of € 1.70 per share.

The net proceeds of the Private Placement will increase AMT's financial flexibility and will be used to fund Glybera® through its regulatory and commercial development and to continue the development of the hemophilia and other pipeline programs.

The payment and delivery of the new shares is expected to take place on October 11, 2010, at which date the new shares are also expected to be admitted to listing on NYSE Euronext in Amsterdam.

Immediately after the closing of the Private Placement, AMT’s issued and outstanding share capital will amount to 23,504,022 ordinary shares.

Pricing Statement

The prospectus that was prepared in relation to the admission to listing and trading of the shares was made generally available on 5 October 2010. Today, AMT deposited a pricing statement with the Authority of the Financial Markets (Stichting Autoriteit Financiële Markten) mentioning amongst others the number of new shares to be issued and the issue price of the new shares. The prospectus and the pricing statement are available via AMT's website.

Kempen & Co and Petercam Nederland N.V. have acted as joint global coordinators and bookrunners for the Private Placement.

About Amsterdam Molecular Therapeutics

AMT is a leader in the development of human gene based therapies. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. This proprietary platform can be applied to a large number of rare (orphan) diseases that are caused by one faulty gene. Currently, AMT has a product pipeline with several AAV-based gene therapy products in LPLD, Hemophilia B, Duchenne Muscular Dystrophy, Acute Intermittent Porphyria, and Parkinson’s Disease at different stages of research or development. AMT was founded in 1998 and is based in Amsterdam.

About Gilde Healthcare Partners

Gilde Healthcare Partners founded in 2000 is headquartered in Utrecht, the Netherlands with representatives in London and Madrid. Gilde Healthcare Partners has over EUR 300 million under management and is actively looking to lead new investments in therapeutics, diagnostics, medical devices, enabling technologies and healthcare services. Gilde is a successful builder of healthcare businesses across Europe. By investing in companies with clear achievable business models, Gilde has used its financial resources and network to create significant value for both its investors and the entrepreneurs it backs. 

Companies that Gilde Healthcare Partners has pro-actively supported span all aspects of healthcare and include Ablynx (Belgium), Acacia (UK), Agendia (Netherlands), AMT (Netherlands), Ascendis (Denmark), BG Medicine (US), Chroma Therapeutics (UK), Conatus (US), Flowcardia (US), Glycart (Switzerland), Innate Pharma (France), Pieris (Germany), Profibrix, Santaris (Denmark) and Symphogen (Denmark).

Gilde Healthcare II is supported by the European Communities Growth and Employment Initiative, MAP - ETF Start up Facility.